"Pyrimidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.
| Descriptor ID |
D011744
|
| MeSH Number(s) |
D03.383.742.698
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidinones".
This graph shows the total number of publications written about "Pyrimidinones" by people in this website by year, and whether "Pyrimidinones" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 5 | 1 | 6 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 3 | 6 |
| 2007 | 2 | 5 | 7 |
| 2008 | 6 | 6 | 12 |
| 2009 | 7 | 4 | 11 |
| 2010 | 5 | 4 | 9 |
| 2011 | 5 | 1 | 6 |
| 2012 | 6 | 4 | 10 |
| 2013 | 4 | 3 | 7 |
| 2014 | 7 | 4 | 11 |
| 2015 | 7 | 11 | 18 |
| 2016 | 11 | 9 | 20 |
| 2017 | 5 | 17 | 22 |
| 2018 | 4 | 7 | 11 |
| 2019 | 5 | 9 | 14 |
| 2020 | 10 | 6 | 16 |
| 2021 | 3 | 7 | 10 |
| 2022 | 3 | 6 | 9 |
| 2023 | 0 | 5 | 5 |
| 2024 | 9 | 5 | 14 |
Below are the most recent publications written about "Pyrimidinones" by people in Profiles.
-
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2025 Feb; 210(1):179-189.
-
Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. Proc Natl Acad Sci U S A. 2024 Oct 15; 121(42):e2317694121.
-
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024 Dec; 35(12):1138-1147.
-
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group. Cancer Discov. 2024 Sep 04; 14(9):1590-1598.
-
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest. 2025 Feb; 167(2):425-435.
-
Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy. Laryngoscope. 2025 Jan; 135(1):478-484.
-
Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations. Clin Lung Cancer. 2024 Dec; 25(8):732-737.
-
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801.
-
Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model. Pediatr Hematol Oncol. 2024 Aug; 41(5):367-375.
-
Generation of a highly specific recombinant full-length antibody for detecting ethirimol in fruit and environmental water. J Hazard Mater. 2024 05 05; 469:134067.